Shares of Keryx Biopharmaceuticals Inc. (KERX) climbed more than 6% in the extended session Tuesday after The Baupost Group, L.L.C. disclosed in a regulatory filing ( SC 13D ) with the Securities and Exchange Commission (SEC) a 34.61% stake (42,016,276 shares) in the company
Keryx Biopharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products geared towards addressing unmet needs and providing unique and meaningful advantages to patients with renal disease and their healthcare providers.
Brokerage firm Barclays raised its price target on shares of Avalonbay Communities Inc. (AVB) from $184.00 to $199.00, while maintaining an Equal Weight rating.
AvalonBay will release its third quarter 2015 earnings on October 26, 2015 after the market close. The company recently said that it expects total rental revenue for Established Communities for the period to increase between 5.4% and 5.5% year over year.
AvalonBay is an equity REIT in the business of developing, redeveloping, acquiring and managing apartment communities in the leading metropolitan areas in New England, the New York/New Jersey Metro area, the Mid-Atlantic, the Pacific Northwest, and the Northern and Southern California regions of the United States.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer